Intrinsic Therapeutics
$454.5K 1,129 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Gamida Cell Inc.
Gamida Cell Inc. reported $452,014.45 across General Payments, Research, and Ownership to 9 physicians and teaching hospitals across 21 transactions.
- $452.0K Above-median payer
- All-tracks total
- 21 Below-median volume
- Transactions
- 9 Below-median reach
- Recipients
- −$111.0K
- General Payments vs PY2023
Gamida Cell Inc. reported $452,014.45 across all CMS Open Payments tracks (General + Research + Ownership) to 9 physicians and teaching hospitals in Program Year 2024 - ranking #786 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $41,735.52, averaging $50.2K per recipient.
How Gamida Cell Inc.'s $452.0K all-tracks total breaks down
Gamida Cell Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
14/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer gamida-cell-inc-1927 Gamida Cell Inc.
$452.0K · #786/1,925 · 0.0% industry · PY2024
- TOT $452.0K
- RANK #786
- SHARE 0.0%
- TXN 21
- RCP 9
- CAT 2
- GEN $41.7K
- ΔGEN −$111.0K
- TOP1 94.9%
- PY 2024
Volume peers
Nearest volume peer: Intrinsic Therapeutics ($454.5K)
Gamida Cell Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Gamida Cell Inc.'s CMS-reported General Payments decreased by $111.0K (−72.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: GAMIDA CELL INC.PY2024: Gamida Cell Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $152,716.72
- PY2024
- $41,735.52
What the Data Shows for Gamida Cell Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Gamida Cell Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
4 transactions worth $41.3K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 98.9% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Gamida Cell Inc. made 2 types of general payments. "Consulting Fee" is the largest category at $41.3K, 98.9% of General Payments.
How Gamida Cell Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $41.3K | 4 | 98.9% |
| Food and Beverage | $463.52 | 5 | 1.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $41,608.54 (99.7%) of $41,735.52 in this company's General Payments records across 7 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Gamida Cell Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Ivan Borrello
$39,622.00 across 3 reported transactions
- 2
Caridad Martinez
$1,650.00 across 1 reported transactions
- 3
Donna Salzman
$112.18 across 1 reported transactions
- 4
Joan Adams
$112.18 across 1 reported transactions
- 5
Kadee J Raser
$112.18 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Gamida Cell Inc. ranks #786 of 1,925 by total payments (top 41% by spend) but is notably more concentrated than that alone would suggest -- #170 of 1,838 by HHI (top 9% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Brahms GmbH : $71.8K total payments, HHI 9287
- VisionAir Solutions, LLC : $81.4K total payments, HHI 9154
- Beyond Air, Inc. : $141.7K total payments, HHI 9142
- Vibrant Gastro, Inc. : $48.6K total payments, HHI 9128
- Sentynl Therapeutics, Inc. : $245.9K total payments, HHI 9110
- Hinge Health, Inc. : $20.8K total payments, HHI 9104
- Gamida Cell Inc. (this company) : $41.7K total payments, HHI 9029
- Next Orthosurgical, Inc : $7.7K total payments, HHI 9013
- Nippon Shinyaku Co.,Ltd : $22.7K total payments, HHI 8998
- Karl Storz Endovision, Inc. : $5.5K total payments, HHI 8973
- Erbe Elektromedizin GmbH : $1.8K total payments, HHI 8938
- Genetesis, Inc. : $17.5K total payments, HHI 8922
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Gamida Cell Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Gamida Cell Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Gamida Cell Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Molnlycke Health Care Ab
$449.3K 0 recipients
Compare payment profiles
Premia Spine, Ltd.
$455.3K 0 recipients
Compare payment profiles
Nuwellis, Inc.
$447.8K 251 recipients
Compare payment profiles
Virtual Incision Corporation
$447.4K 683 recipients
Compare payment profiles
BSN Medical Inc
$445.4K 328 recipients
Compare payment profiles
Put this to use
Gamida Cell Inc. ranks #786 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Gamida Cell Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.